公开(公告)号：EP2042594A1

公开(公告)日：2009-04-01

申请号：EP08016978.2

申请日：2001-11-16

申请人： Kirin Pharma Kabushiki Kaisha

发明人： Robl, James M. ,  Kuroiwa, Yoshimi ,  Tomizuka, Kazuma ,  Ishida, Isao

IPC分类号： C12N15/00 ,  C12P21/00 ,  A01K67/033 ,  A01K67/027

CPC分类号： C12N15/8509 ,  A01K67/0273 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/101 ,  A01K2267/01 ,  C12N9/1051 ,  C12N2800/30

摘要： The present invention relates to the production of a transgenic bovine which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results on the expression of non-bovine antibodies, preferably human antibodies.

摘要翻译： 本发明涉及转基因牛的生产，其包含导致其内源性抗体失活和丧失表达的遗传修饰，以及异源抗体（优选人抗体）的表达。 这通过IgM重链表达的失活和任选地通过Ig轻链表达的失活以及进一步引入导致非牛抗体（优选人抗体）表达的人造染色体来实现。